Rational urine drug monitoring in patients receiving opioids for chronic pain: Consensus recommendations

Charles E. Argoff, Daniel P. Alford, Jeffrey Fudin, Jeremy A. Adler, Matthew Bair, Richard C. Dart, Roy Gandolfi, Bill H. McCarberg, Steven P. Stanos, Jeffrey A. Gudin, Rosemary C. Polomano, Lynn R. Webster

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Objective. To develop consensus recommendations on urine drug monitoring (UDM) in patients with chronic pain who are prescribed opioids. Methods. An interdisciplinary group of clinicians with expertise in pain, substance use disorders, and primary care conducted virtual meetings to review relevant literature and existing guidelines and share their clinical experience in UDM before reaching consensus recommendations. Results. Definitive (e.g., chromatography-based) testing is recommended as most clinically appropriate for UDM because of its accuracy; however, institutional or payer policies may require initial use of presumptive testing (i.e., immunoassay). The rational choice of substances to analyze for UDM involves considerations that are specific to each patient and related to illicit drug availability. Appropriate opioid risk stratification is based on patient history (especially psychiatric conditions or history of opioid or substance use disorder), prescription drug monitoring program data, results from validated risk assessment tools, and previous UDM. Urine drug monitoring is suggested to be performed at baseline for most patients prescribed opioids for chronic pain and at least annually for those at low risk, two or more times per year for those at moderate risk, and three or more times per year for those at high risk. Additional UDM should be performed as needed on the basis of clinical judgment. Conclusions. Although evidence on the efficacy of UDM in preventing opioid use disorder, overdose, and diversion is limited, UDM is recommended by the panel as part of ongoing comprehensive risk monitoring in patients prescribed opioids for chronic pain.

Original languageEnglish (US)
Article numberpnx285
Pages (from-to)97-117
Number of pages21
JournalPain Medicine (United States)
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Drug Monitoring
Chronic Pain
Opioid Analgesics
Consensus
Urine
Substance-Related Disorders
Prescription Drugs
Physiologic Monitoring
Street Drugs
Immunoassay
Psychiatry
Chromatography
Primary Health Care
Guidelines
Pain

Keywords

  • Chronic Pain
  • Opioids
  • Pain Management
  • Screening Tools
  • Substance Use Disorders
  • Urine Drug Monitoring

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Argoff, C. E., Alford, D. P., Fudin, J., Adler, J. A., Bair, M., Dart, R. C., ... Webster, L. R. (2018). Rational urine drug monitoring in patients receiving opioids for chronic pain: Consensus recommendations. Pain Medicine (United States), 19(1), 97-117. [pnx285]. https://doi.org/10.1093/pm/pnx285

Rational urine drug monitoring in patients receiving opioids for chronic pain : Consensus recommendations. / Argoff, Charles E.; Alford, Daniel P.; Fudin, Jeffrey; Adler, Jeremy A.; Bair, Matthew; Dart, Richard C.; Gandolfi, Roy; McCarberg, Bill H.; Stanos, Steven P.; Gudin, Jeffrey A.; Polomano, Rosemary C.; Webster, Lynn R.

In: Pain Medicine (United States), Vol. 19, No. 1, pnx285, 01.01.2018, p. 97-117.

Research output: Contribution to journalReview article

Argoff, CE, Alford, DP, Fudin, J, Adler, JA, Bair, M, Dart, RC, Gandolfi, R, McCarberg, BH, Stanos, SP, Gudin, JA, Polomano, RC & Webster, LR 2018, 'Rational urine drug monitoring in patients receiving opioids for chronic pain: Consensus recommendations', Pain Medicine (United States), vol. 19, no. 1, pnx285, pp. 97-117. https://doi.org/10.1093/pm/pnx285
Argoff, Charles E. ; Alford, Daniel P. ; Fudin, Jeffrey ; Adler, Jeremy A. ; Bair, Matthew ; Dart, Richard C. ; Gandolfi, Roy ; McCarberg, Bill H. ; Stanos, Steven P. ; Gudin, Jeffrey A. ; Polomano, Rosemary C. ; Webster, Lynn R. / Rational urine drug monitoring in patients receiving opioids for chronic pain : Consensus recommendations. In: Pain Medicine (United States). 2018 ; Vol. 19, No. 1. pp. 97-117.
@article{2a7904cb700443cb8bcdb1cbc7543730,
title = "Rational urine drug monitoring in patients receiving opioids for chronic pain: Consensus recommendations",
abstract = "Objective. To develop consensus recommendations on urine drug monitoring (UDM) in patients with chronic pain who are prescribed opioids. Methods. An interdisciplinary group of clinicians with expertise in pain, substance use disorders, and primary care conducted virtual meetings to review relevant literature and existing guidelines and share their clinical experience in UDM before reaching consensus recommendations. Results. Definitive (e.g., chromatography-based) testing is recommended as most clinically appropriate for UDM because of its accuracy; however, institutional or payer policies may require initial use of presumptive testing (i.e., immunoassay). The rational choice of substances to analyze for UDM involves considerations that are specific to each patient and related to illicit drug availability. Appropriate opioid risk stratification is based on patient history (especially psychiatric conditions or history of opioid or substance use disorder), prescription drug monitoring program data, results from validated risk assessment tools, and previous UDM. Urine drug monitoring is suggested to be performed at baseline for most patients prescribed opioids for chronic pain and at least annually for those at low risk, two or more times per year for those at moderate risk, and three or more times per year for those at high risk. Additional UDM should be performed as needed on the basis of clinical judgment. Conclusions. Although evidence on the efficacy of UDM in preventing opioid use disorder, overdose, and diversion is limited, UDM is recommended by the panel as part of ongoing comprehensive risk monitoring in patients prescribed opioids for chronic pain.",
keywords = "Chronic Pain, Opioids, Pain Management, Screening Tools, Substance Use Disorders, Urine Drug Monitoring",
author = "Argoff, {Charles E.} and Alford, {Daniel P.} and Jeffrey Fudin and Adler, {Jeremy A.} and Matthew Bair and Dart, {Richard C.} and Roy Gandolfi and McCarberg, {Bill H.} and Stanos, {Steven P.} and Gudin, {Jeffrey A.} and Polomano, {Rosemary C.} and Webster, {Lynn R.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/pm/pnx285",
language = "English (US)",
volume = "19",
pages = "97--117",
journal = "Pain Medicine",
issn = "1526-2375",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Rational urine drug monitoring in patients receiving opioids for chronic pain

T2 - Consensus recommendations

AU - Argoff, Charles E.

AU - Alford, Daniel P.

AU - Fudin, Jeffrey

AU - Adler, Jeremy A.

AU - Bair, Matthew

AU - Dart, Richard C.

AU - Gandolfi, Roy

AU - McCarberg, Bill H.

AU - Stanos, Steven P.

AU - Gudin, Jeffrey A.

AU - Polomano, Rosemary C.

AU - Webster, Lynn R.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective. To develop consensus recommendations on urine drug monitoring (UDM) in patients with chronic pain who are prescribed opioids. Methods. An interdisciplinary group of clinicians with expertise in pain, substance use disorders, and primary care conducted virtual meetings to review relevant literature and existing guidelines and share their clinical experience in UDM before reaching consensus recommendations. Results. Definitive (e.g., chromatography-based) testing is recommended as most clinically appropriate for UDM because of its accuracy; however, institutional or payer policies may require initial use of presumptive testing (i.e., immunoassay). The rational choice of substances to analyze for UDM involves considerations that are specific to each patient and related to illicit drug availability. Appropriate opioid risk stratification is based on patient history (especially psychiatric conditions or history of opioid or substance use disorder), prescription drug monitoring program data, results from validated risk assessment tools, and previous UDM. Urine drug monitoring is suggested to be performed at baseline for most patients prescribed opioids for chronic pain and at least annually for those at low risk, two or more times per year for those at moderate risk, and three or more times per year for those at high risk. Additional UDM should be performed as needed on the basis of clinical judgment. Conclusions. Although evidence on the efficacy of UDM in preventing opioid use disorder, overdose, and diversion is limited, UDM is recommended by the panel as part of ongoing comprehensive risk monitoring in patients prescribed opioids for chronic pain.

AB - Objective. To develop consensus recommendations on urine drug monitoring (UDM) in patients with chronic pain who are prescribed opioids. Methods. An interdisciplinary group of clinicians with expertise in pain, substance use disorders, and primary care conducted virtual meetings to review relevant literature and existing guidelines and share their clinical experience in UDM before reaching consensus recommendations. Results. Definitive (e.g., chromatography-based) testing is recommended as most clinically appropriate for UDM because of its accuracy; however, institutional or payer policies may require initial use of presumptive testing (i.e., immunoassay). The rational choice of substances to analyze for UDM involves considerations that are specific to each patient and related to illicit drug availability. Appropriate opioid risk stratification is based on patient history (especially psychiatric conditions or history of opioid or substance use disorder), prescription drug monitoring program data, results from validated risk assessment tools, and previous UDM. Urine drug monitoring is suggested to be performed at baseline for most patients prescribed opioids for chronic pain and at least annually for those at low risk, two or more times per year for those at moderate risk, and three or more times per year for those at high risk. Additional UDM should be performed as needed on the basis of clinical judgment. Conclusions. Although evidence on the efficacy of UDM in preventing opioid use disorder, overdose, and diversion is limited, UDM is recommended by the panel as part of ongoing comprehensive risk monitoring in patients prescribed opioids for chronic pain.

KW - Chronic Pain

KW - Opioids

KW - Pain Management

KW - Screening Tools

KW - Substance Use Disorders

KW - Urine Drug Monitoring

UR - http://www.scopus.com/inward/record.url?scp=85041288198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041288198&partnerID=8YFLogxK

U2 - 10.1093/pm/pnx285

DO - 10.1093/pm/pnx285

M3 - Review article

C2 - 29206984

AN - SCOPUS:85041288198

VL - 19

SP - 97

EP - 117

JO - Pain Medicine

JF - Pain Medicine

SN - 1526-2375

IS - 1

M1 - pnx285

ER -